BACKGROUND: Anemia is frequent in patients with cancer, but there are concerns regarding treatment with erythropoiesis-stimulating agents. Blood transfusions are commonly used as an alternative, but with little data regarding outcomes. METHODS: In a retrospective cohort study, we investigated the associations between transfusions and venous thromboembolism, arterial thromboembolism, and mortality in hospitalized patients with cancer using the discharge database of the University HealthSystem Consortium, which included 504 208 hospitalizations of patients with cancer between 1995 and 2003 at 60 US medical centers. RESULTS: Of the patients included, 70 542 (14.0%) received at least 1 red blood cell (RBC) transfusion and 15 237 (3.0%) received at least 1 platelet transfusion. Of patients receiving RBC transfusions, 7.2% developed venous thromboembolism and 5.2% developed arterial thromboembolism, and this was significantly greater than the rates of 3.8% and 3.1%, respectively, for the remaining study population (P < .001). In multivariate analysis, RBC transfusion (odds ratio [OR], 1.60; 95% confidence interval [CI], 1.53-1.67) and platelet transfusion (1.20; 1.11-1.29) were independently associated with an increased risk of venous thromboembolism. Both RBC transfusion (OR, 1.53; 95% CI, 1.46-1.61) and platelet transfusion (1.55; 1.40-1.71) were also associated with arterial thromboembolism (P < .001 for each). Transfusions were also associated with an increased risk of in-hospital mortality (RBCs: OR, 1.34; 95% CI, 1.29-1.38; platelets: 2.40; 2.27-2.52; P < .001). CONCLUSIONS: Both RBC and platelet transfusions are associated with increased risks of venous and arterial thrombotic events and mortality in hospitalized patients with cancer. Further investigation is necessary to determine whether this relationship is causal.
BACKGROUND:Anemia is frequent in patients with cancer, but there are concerns regarding treatment with erythropoiesis-stimulating agents. Blood transfusions are commonly used as an alternative, but with little data regarding outcomes. METHODS: In a retrospective cohort study, we investigated the associations between transfusions and venous thromboembolism, arterial thromboembolism, and mortality in hospitalized patients with cancer using the discharge database of the University HealthSystem Consortium, which included 504 208 hospitalizations of patients with cancer between 1995 and 2003 at 60 US medical centers. RESULTS: Of the patients included, 70 542 (14.0%) received at least 1 red blood cell (RBC) transfusion and 15 237 (3.0%) received at least 1 platelet transfusion. Of patients receiving RBC transfusions, 7.2% developed venous thromboembolism and 5.2% developed arterial thromboembolism, and this was significantly greater than the rates of 3.8% and 3.1%, respectively, for the remaining study population (P < .001). In multivariate analysis, RBC transfusion (odds ratio [OR], 1.60; 95% confidence interval [CI], 1.53-1.67) and platelet transfusion (1.20; 1.11-1.29) were independently associated with an increased risk of venous thromboembolism. Both RBC transfusion (OR, 1.53; 95% CI, 1.46-1.61) and platelet transfusion (1.55; 1.40-1.71) were also associated with arterial thromboembolism (P < .001 for each). Transfusions were also associated with an increased risk of in-hospital mortality (RBCs: OR, 1.34; 95% CI, 1.29-1.38; platelets: 2.40; 2.27-2.52; P < .001). CONCLUSIONS: Both RBC and platelet transfusions are associated with increased risks of venous and arterial thrombotic events and mortality in hospitalized patients with cancer. Further investigation is necessary to determine whether this relationship is causal.
Authors: Filiz Akbiyik; Denise M Ray; Kelly F Gettings; Neil Blumberg; Charles W Francis; Richard P Phipps Journal: Blood Date: 2004-05-06 Impact factor: 22.113
Authors: Bruce D Spiess; David Royston; Jerrold H Levy; Jane Fitch; Wulf Dietrich; Simon Body; John Murkin; Andrea Nadel Journal: Transfusion Date: 2004-08 Impact factor: 3.157
Authors: Henrik Hjalgrim; Gustaf Edgren; Klaus Rostgaard; Marie Reilly; Trung Nam Tran; Kjell Einar Titlestad; Agneta Shanwell; Casper Jersild; Johanna Adami; Agneta Wikman; Gloria Gridley; Louise Wideroff; Olof Nyrén; Mads Melbye Journal: J Natl Cancer Inst Date: 2007-12-11 Impact factor: 13.506
Authors: Sunil V Rao; James G Jollis; Robert A Harrington; Christopher B Granger; L Kristin Newby; Paul W Armstrong; David J Moliterno; Lauren Lindblad; Karen Pieper; Eric J Topol; Jonathan S Stamler; Robert M Califf Journal: JAMA Date: 2004-10-06 Impact factor: 56.272
Authors: Julie Sahler; Katie Grimshaw; Sherry L Spinelli; Majed A Refaai; Richard P Phipps; Neil Blumberg Journal: Drug Discov Today Dis Mech Date: 2011-07-20
Authors: Jean-Luc Canon; Johan Vansteenkiste; Michael Hedenus; Pere Gascon; Carsten Bokemeyer; Heinz Ludwig; Jan Vermorken; Jason Legg; Beatriz Pujol; Ken Bridges Journal: Med Oncol Date: 2011-11-13 Impact factor: 3.064
Authors: Monisha A Kumar; Torrey A Boland; Mohamed Baiou; Michael Moussouttas; Jay H Herman; Rodney D Bell; Robert H Rosenwasser; Scott E Kasner; Valerie E Dechant Journal: Neurocrit Care Date: 2014-02 Impact factor: 3.210
Authors: Amy E DeZern; Katherine Williams; Marianna Zahurak; Wesley Hand; R Scott Stephens; Karen E King; Steven M Frank; Paul M Ness Journal: Transfusion Date: 2016-05-20 Impact factor: 3.157
Authors: Neil Blumberg; Sherry L Spinelli; Charles W Francis; Mark B Taubman; Richard P Phipps Journal: Immunol Res Date: 2009-01-29 Impact factor: 2.829